Skip to main content
. 2017 Dec 1;3(3):555–572. doi: 10.1016/j.ekir.2017.11.019

Table 2.

Selected miRNAs showing differential concentration changes between non-MA and MA persistent patients

Starting fraction miRNA PMA:NO-AVE (log2CPM) PMA:MA-AVE (log2CPM) Log2FC P
Urine hsa-miR-133a-1-3p 5.97 8.40 2.43 0.0254
hsa-miR-31-5p 7.95 9.81 1.85 0.0498
hsa-miR-122-5p 8.96 10.48 1.52 0.0097
hsa-miR-99b-5p 10.57 11.99 1.43 0.0324
hsa-miR-92b-3p 8.29 9.49 1.21 0.0282
hsa-miR-181b-1-5p 9.44 10.49 1.05 0.0077
EV hsa-miR-182-5p 9.80 11.32 1.52 0.0446
hsa-miR-200c-3p 11.83 13.58 1.76 0.0483
hsa-miR-30d-5p 13.48 14.59 1.11 0.0414
hsa-miR-31-5p 8.74 10.92 2.17 0.0457
hsa-miR-335-5p 10.40 11.21 0.81 0.0142
hsa-miR-96-5p 7.75 8.90 1.15 0.0298

AVE, average; CPM, counts per million; EV, extracellular vesicle; FC, fold change; MA, microalbuminuria; miRNA, microRNA; PMA:NO, Persistent MA: non-MA cycle; PMA:MA, Persistent MA:MA cycle.

See Supplementary Table S3 for additional details.